Currax Pharmaceuticals CEO says the GLP-1 conversation isn’t one-size-fits-all

Currax Pharmaceuticals CEO George Hampton talks with Digital Editor Jack O'Brien about the ascendance of GLP-1 drugs and how weight loss drugs are changing the obesity narrative. Though brand names like Mounjaro, Ozempic, Zepbound and Wegovy have captured the public’s attention in recent months, Hampton says there’s a place for Currax’ Contrave medication in the pricing and access discussion.

Additionally, senior reporter Lecia Bushak recaps the Biden administration’s moves this week to protect abortion rights by strengthening HIPAA.

For the Trends segment, Jack and Lecia dive into Dr. Jen Ashton’s pending departure from ABC News to launch her women’s wellness company Ajenda, Allergan Aesthetics’ casting call to be the face of Botox and Elanco Health’s Parvo is Poop push for pooches.

Check us out at: mmm-online.com

Follow us:

YouTube: @MMM-online

TikTok: @MMMnews

Instagram: @MMMnewsonline

Twitter/X: @MMMnews

LinkedIn: MM+M

To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Music: “Deep Reflection” by DP and Triple Scoop Music.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.